2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.
October 25, 2017
Article
Rachel A. Freedman, MD, discusses treating patients with HER2-positive breast cancer who develop CNS metastases, and the promise that neratinib holds in this patient population.
September 21, 2017
Video
Dominick Bosse, MD, fellow, Dana-Farber Cancer Institute, discusses the rationale behind combining VEGF-targeted therapies and radium-223 dichloride (Xofigo) in metastatic renal cell carcinoma.
September 19, 2017
Video
Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, discusses the future of treatment for renal cell carcinoma.
September 08, 2017
Video
Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses pertuzumab (Perjeta) in patients with HER2-positive breast cancer.
September 06, 2017
Article
In an ongoing phase II trial, researchers are investigating several targeted agents for use in the treatment of patients with glioblastoma (GBM).
June 29, 2017
Video
Rachel A. Freedman, MD, MPH, associate clinical director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, senior physician, assistant professor of medicine, Harvard Medical School, discusses dual HER2-targeted therapies in breast cancer.
June 27, 2017
Article
Jennifer Ligibel, MD, describes the BWEL trial and the possible impact of weight loss intervention for patients with breast cancer.
June 13, 2017
Article
Researchers at Dana-Farber Cancer Institute and Brigham and Women’s Hospital are attempting to improve personalized medicine by analyzing DNA samples for known cancer biomarkers.
May 31, 2017
Video
Anna Farago, MD, PhD, Massachusetts General Hospital Cancer Center, instructor of Medicine at Harvard Medical School, discusses opportunities for the development of biomarkers for patients with small cell lung cancer (SCLC).
May 30, 2017
Article
Results from the KEYNOTE-028 study showed that pembrolizumab (Keytruda) was associated with a median duration of response of 6 months and a 6-month progression-free survival rate of 40.4% in women with advanced PD-L1–positive endometrial cancer.
May 23, 2017
Video
Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses toxicities associated with PARP inhibitors in ovarian cancer.
May 03, 2017
Video
Matthew B. Yurgelun, MD, assistant professor of Medicine, Harvard Medical School, and a researcher at the Dana-Farber Cancer Institute, discusses germline testing in colorectal cancer.
May 02, 2017
Video
Suzanne George, MD, assistant professor of Medicine, Harvard Medical School, clinical director, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, discusses a study exploring the efficacy of a PD-1 inhibitor in patients with uterine leiomyosarcoma.
April 26, 2017
Video
Ursula A. Matulonis, MD, professor of Medicine, Harvard Medical School, medical director of Gynecologic Oncology, Dana-Farber Cancer Institute, discusses maintenance therapy in ovarian cancer.
April 24, 2017
Article
Suzanne George, MD, discusses an exceptional responder to pembrolizumab in leiomyosarcoma and the significance of these findings for further immunotherapy advances in the field.
April 24, 2017
Video
Anna Farago, MD, PhD, assistant, Medicine, Massachusetts General Hospital Cancer Center, and instructor, Medicine, at Harvard Medical School, discusses the combination of olarparib (Lynparza) and temozolomide (Temodar) for patients with small cell lung cancer (SCLC).
April 13, 2017
Video
Toni Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses savolitinib in papillary renal cell cancer.
April 13, 2017
Video
Andrew A. Lane, MD, PhD, physician, assistant professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the identification of a rare blood disorder called blastic plasmacytoid dendritic cell neoplasm.
April 01, 2017
Article
Ursula A. Matulonis, MD, discusses the latest regulatory advances with PARP inhibitors and their continued growth in the treatment of patients with ovarian cancer.
March 29, 2017
Video
Jochen H. Lorch, MD, director, Thyroid Cancer Center, Dana-Farber Cancer Institute, assistant professor of Medicine, Harvard Medical School, discusses the current treatment landscape of medullary thyroid cancer.